Workflow
Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal
DaxorDaxor(US:DXR) GlobeNewswire News Room·2025-05-14 12:00

Core Insights - Daxor Corporation has announced significant findings from Duke University Medical Center regarding the effectiveness of Blood Volume Analysis (BVA) in identifying anemia types in heart failure patients [1][3] - The study emphasizes that standard blood tests are insufficient for accurately diagnosing anemia, highlighting the need for BVA in clinical practice [2][3] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, with its BVA-100® being the only FDA-cleared diagnostic test for quantifying blood volume status [4] - The company has conducted over 70,000 tests across leading hospitals in the U.S., contributing to improved patient outcomes in heart failure and critical care [4] Research Findings - The study revealed that among heart failure patients diagnosed with anemia, 60% had true anemia while 40% had dilutional pseudo-anemia, indicating a critical distinction in treatment needs [6] - Patients with dilutional pseudo-anemia experienced higher hospitalization rates compared to those with no anemia or true anemia, underscoring the importance of accurate anemia classification [6] - Heart failure patients with true anemia or RBCM deficit showed poorer exercise capacity, linking anemia type to patient outcomes [6]